Clinical Trial Update: A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating iodine-131–labeled metuximab in combination with cytokine-induced killer cells to prevent hepatocellular carcinoma; current st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CIK cells therapy (cytokine-induced killer cells)
• Iodine-131 Metuximab Injection (Iodine-131 labeled metuximab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Multiple Drug Use | Phase 4 | Status: UNKNOWN